What is the 13F Pro Quality Score for RARE?

13F Pro ranks Ultragenyx Pharmaceutical Inc. (RARE) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View RARE's current score at https://13fpro.ai/research/RARE (free sign-up required for the full ranking).

Which hedge funds own the most RARE stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of RARE include BlackRock,, VANGUARD PORTFOLIO MANAGEMENT, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/RARE as soon as new 13F filings post.

Where does 13F Pro source RARE data?

All Ultragenyx Pharmaceutical Inc. fundamentals and ownership data come directly from SEC EDGAR. Ultragenyx Pharmaceutical Inc. files with the SEC under CIK 1515673. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is RARE in?

Ultragenyx Pharmaceutical Inc. (RARE) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is RARE research updated on 13F Pro?

RARE's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Ultragenyx Pharmaceutical Inc.(RARE)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1515673 RARE stock profile & AI dashboard →

13F Pro Quality Score

31.0/100

Rank #2,330 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

81.0/100

Profitability

7.3/100

Balance Sheet

4.7/100

Earnings Quality

30.0/100

Free Cash Flow

7.1/100

Institutional Flow

73.5/100

Revenue Scale

39.8/100

Dilution Risk

8.3/100

RARE Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Ultragenyx Pharmaceutical Inc. (RARE), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RARE at 31.0/100 on a 32-signal composite quality model, placing it at rank #2,330 of 2,879 stocks — the bottom half of the AI-ranked universe. RARE scores in the top quartile across revenue growth (81.0). Areas of concern include balance sheet strength (4.7) and free cash flow (7.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 8.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Ultragenyx Pharmaceutical Inc. reports quarterly revenue of $136.0M, net income of $-185.0M, free cash flow of $-198.0M. Top institutional holders of RARE by reported 13-F value include BlackRock,, VANGUARD PORTFOLIO MANAGEMENT, STATE STREET, based on the most recent SEC filings. RARE trades on the Nasdaq exchange and files with the SEC under CIK 1515673. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RARE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Ultragenyx Pharmaceutical Inc. directly from SEC EDGAR. Ultragenyx Pharmaceutical Inc.'s 13F Pro composite quality score has ranged between 8 and 67 since 2021, currently 31.0 — a stable long-term trajectory across 56 quarterly and live scoring snapshots.

Revenue

Q1 2026

$136.0M

Net Income

Q1 2026

$-185.0M

Free Cash Flow

Q1 2026

$-198.0M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+20.2% YoY

$673.0MFY 2025

FY21 $351.4MFY22 $363.3MFY24 $560.0MFY25 $673.0M

Net Income

-1.1% YoY

$-575.0MFY 2025

FY21 $-454.0MFY22 $-707.4MFY24 $-569.0MFY25 $-575.0M

Operating Income

+0.2% YoY

$-535.0MFY 2025

FY21 $-381.7MFY22 $-648.9MFY24 $-536.0MFY25 $-535.0M

EPS (Diluted)

+7.3% YoY

$-5.83FY 2025

FY21 $-6.70FY22 $-10.12FY24 $-6.29FY25 $-5.83

Total Assets

+1.9% YoY

$1.53BFY 2025

FY21 $1.52BFY22 $1.55BFY24 $1.50BFY25 $1.53B

Op. Cash Flow

-12.6% YoY

$-466.0MFY 2025

FY21 $-338.7MFY22 $-380.5MFY24 $-414.0MFY25 $-466.0M

Metric	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$673.0M +20.2%	$560.0M +54.1%	$363.3M +3.4%	$351.4M +29.7%	$271.0M +161.3%	$103.7M
Net Income	$-575.0M -1.1%	$-569.0M +19.6%	$-707.4M -55.8%	$-454.0M -143.4%	$-186.6M +53.7%	$-402.7M
Operating Income	$-535.0M +0.2%	$-536.0M +17.4%	$-648.9M -70.0%	$-381.7M -15.6%	$-330.1M +22.2%	$-424.2M
EPS (Diluted)	$-5.83 +7.3%	$-6.29 +37.8%	$-10.12 -51.0%	$-6.70 -118.2%	$-3.07	—
Total Assets	$1.53B +1.9%	$1.50B -2.7%	$1.55B +1.5%	$1.52B -13.5%	$1.76B +55.0%	$1.14B
Operating Cash Flow	$-466.0M -12.6%	$-414.0M -8.8%	$-380.5M -12.3%	$-338.7M -156.2%	$-132.2M +61.7%	$-345.4M

AI Insight: RARE Financial Trends

Ultragenyx equity has been fully consumed — book value turned negative in Q4 2025 and worsened to -$236M in Q1 2026 as losses persist.

• Equity collapsed from $432M in Q2 2024 to -$236M in Q1 2026, an $668M erosion over six quarters.

• Operating cash outflow surged to -$197M in Q1 2026, the worst quarter on record in this dataset.

• Revenue reached $207M in Q4 2025 — the highest in the period — but slipped back to $136M in Q1 2026, the lowest in a year.

• Net losses have ranged from -$115M to -$185M with no sustained improvement; Q1 2026 loss of -$185M is the widest recorded.

⚠ Negative equity of -$236M with no debt data disclosed — hidden leverage could further stress the balance sheet.

⚠ Operating cash burn of -$197M in Q1 2026 raises near-term liquidity questions; cash runway needs monitoring.

⚠ Revenue seasonality is sharp — Q4 2025 at $207M vs. Q1 2026 at $136M — watch whether Q2 2026 rebounds toward prior peaks.

AI Insight: RARE Ratio Trends

Ultragenyx remains deeply unprofitable, with Q1 2026 operating margin hitting a record -124.3% — the worst in the visible dataset.

• Operating margin deteriorated sharply to -124.3% in Q1 2026 from -54.6% in Q4 2025, reversing a brief improvement.

• Net profit margin worsened to -136.0% in Q1 2026, the most negative reading across all periods shown.

• ROA swung to -57.1% in Q1 2026 from -33.6% in Q4 2025, indicating accelerating asset-level losses.

• ROIC and D/E remain unreported across all periods, limiting full capital-efficiency and leverage assessment.

⚠ Q1 appears structurally worse each year: Q1 2025 was -102.6% OpMargin; Q1 2026 deepened to -124.3%.

⚠ TTM OpMargin of -83.8% masks extreme quarterly volatility, ranging from -54.6% to -124.3% in recent quarters.

⚠ Persistent absence of D/E and ROIC data obscures leverage trajectory and true return on invested capital.

Get alerted when RARE's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Ultragenyx Pharmaceutical Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of RARE

BlackRock, Inc.
$152.9M7,299,598 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$112.8M5,385,992 sh
STATE STREET CORP
$105.2M5,021,441 sh
AQR CAPITAL MANAGEMENT LLC
$95.9M4,578,024 sh
VANGUARD CAPITAL MANAGEMENT LLC
$87.8M4,189,831 sh
RTW INVESTMENTS, LP
$76.4M3,648,795 sh
SANDS CAPITAL MANAGEMENT, LLC
$67.3M3,214,533 sh
Sofinnova Ventures Inc
$65.9M3,145,888 sh
WELLINGTON MANAGEMENT GROUP LLP
$55.3M2,640,812 sh
Bellevue Group AG
$49.9M2,380,000 sh

Fund	Value	Shares
BlackRock, Inc.	$152.9M	7,299,598
VANGUARD PORTFOLIO MANAGEMENT LLC	$112.8M	5,385,992
STATE STREET CORP	$105.2M	5,021,441
AQR CAPITAL MANAGEMENT LLC	$95.9M	4,578,024
VANGUARD CAPITAL MANAGEMENT LLC	$87.8M	4,189,831
RTW INVESTMENTS, LP	$76.4M	3,648,795
SANDS CAPITAL MANAGEMENT, LLC	$67.3M	3,214,533
Sofinnova Ventures Inc	$65.9M	3,145,888
WELLINGTON MANAGEMENT GROUP LLP	$55.3M	2,640,812
Bellevue Group AG	$49.9M	2,380,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put RARE on your watchlist

Track score changes the day Ultragenyx Pharmaceutical Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is RARE a good stock to buy?

13F Pro's AI-powered analysis of Ultragenyx Pharmaceutical Inc. (RARE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RARE are available on the RARE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own RARE?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RARE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Ultragenyx Pharmaceutical Inc.'s investment landscape.